-
C.
Clemente,
M.
Mihm,
R.
Bufalino,
S.
Zurrida,
P.
Collini,
N.
Cascinelli
(1996)
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
Cancer, 77
-
Eran
Hodis,
I.
Watson,
G.
Kryukov,
S.
Arold,
M.
Imieliński,
Jean-Philippe
Theurillat,
E.
Nickerson,
D.
Auclair,
Liren
Li,
C.
Place,
D.
Dicara,
A.
Ramos,
M.
Lawrence,
K.
Cibulskis,
A.
Sivachenko,
Douglas
Voet,
G.
Saksena,
Nicolas
Stransky,
R.
Onofrio,
W.
Winckler,
K.
Ardlie,
N.
Wagle,
J.
Wargo,
K.
Chong,
D.
Morton,
K.
Stemke‐Hale,
Guo
Chen,
M.
Noble,
M.
Meyerson,
J.
Ladbury,
M.
Davies,
J.
Gershenwald,
S.
Wagner,
D.
Hoon,
D.
Schadendorf,
E.
Lander,
S.
Gabriel,
G.
Getz,
L.
Garraway,
L.
Chin
(2012)
A Landscape of Driver Mutations in Melanoma
Cell, 150
-
M.
Sini,
V.
Doneddu,
P.
Paliogiannis,
M.
Casula,
M.
Colombino,
A.
Manca,
G.
Botti,
P.
Ascierto,
A.
Lissia,
A.
Cossu,
G.
Palmieri
(2018)
Genetic alterations in main candidate genes during melanoma progression
Oncotarget, 9
-
Huitao
Wang,
Jianhe
Liu,
Kewei
Fang,
Changxing
Ke,
Yongming
Jiang,
Guang
Wang,
Tong-Xin
Yang,
Tao
Chen,
Xin
Shi
(2019)
Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis
BMC Urology, 19
-
A.
Burton,
Brent
Roach,
Michael
Mays,
Andrea
Chen,
Brooke
Ginter,
Abbey
Vierling,
C.
Scoggins,
Robert
Martin,
A.
Stromberg,
L.
Hagendoorn,
K.
McMasters
(2011)
Prognostic Significance of Tumor Infiltrating Lymphocytes in Melanoma
The American Surgeon, 77
-
Rebecca
Taylor,
Ami
Patel,
K.
Panageas,
K.
Busam,
M.
Brady
(2007)
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 7
-
C.
Robert,
B.
Karaszewska,
J.
Schachter,
P.
Rutkowski,
A.
Mackiewicz,
D.
Stroiakovski,
M.
Lichinitser,
R.
Dummer,
F.
Grange,
L.
Mortier,
V.
Chiarion-Sileni,
K.
Drucis,
I.
Krajsová,
A.
Hauschild,
P.
Lorigan,
P.
Wolter,
G.
Long,
K.
Flaherty,
P.
Nathan,
A.
Ribas,
Anne-Marie
Martin,
P.
Sun,
W.
Crist,
J.
Legos,
S.
Rubin,
S.
Little,
D.
Schadendorf
(2015)
Improved overall survival in melanoma with combined dabrafenib and trametinib.
The New England journal of medicine, 372 1
-
Lieping
Chen,
Xue
Han
(2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
The Journal of clinical investigation, 125 9
-
P.
Cooper,
H.
Frierson,
A.
Morrison
(1985)
Malignant transformation of eccrine spiradenoma.
Archives of dermatology, 121 11
-
Anton
Uryvaev,
M.
Passhak,
Dov
Hershkovits,
E.
Sabo,
G.
Bar-Sela
(2018)
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
Medical Oncology, 35
-
Farhad
Azimi,
R.
Scolyer,
Pavlina
Rumcheva,
M.
Moncrieff,
R.
Murali,
S.
McCarthy,
R.
Saw,
J.
Thompson
(2012)
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
-
M.
Efremova,
D.
Rieder,
V.
Klepsch,
P.
Charoentong,
F.
Finotello,
H.
Hackl,
Natascha
Hermann-Kleiter,
M.
Löwer,
G.
Baier,
A.
Krogsdam,
Z.
Trajanoski
(2018)
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Nature Communications, 9
-
M.
Gooden,
De
Bock,
N.
Leffers,
T.
Daemen,
H.
Nijman
(2011)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
British Journal of Cancer, 105
-
B.
Merelli,
D.
Massi,
L.
Cattaneo,
M.
Mandalà
(2014)
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Critical reviews in oncology/hematology, 89 1
-
E.
Eisenhauer,
P.
Therasse,
J.
Bogaerts,
L.
Schwartz,
D.
Sargent,
R.
Ford,
J.
Dancey,
S.
Arbuck,
S.
Gwyther,
M.
Mooney,
Lawrence
Rubinstein,
L.
Shankar,
L.
Dodd,
Robert
Kaplan,
D.
Lacombe,
J.
Verweij
(2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
European journal of cancer, 45 2
-
C.
Curiel-Lewandrowski,
Suephy
Chen,
S.
Swetter,
on
Sub-Committee
(2012)
Screening and Prevention Measures for Melanoma: Is There a Survival Advantage?
Current Oncology Reports, 14
-
S.
Diem,
Omar
Ali,
C.
Ackermann,
D.
Bomze,
V.
Koelzer,
W.
Jochum,
D.
Speiser,
K.
Mertz,
L.
Flatz
(2017)
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
Cancer Immunology, Immunotherapy, 67
-
S.
Weiss,
S.
Han,
K.
Lui,
J.
Tchack,
R.
Shapiro,
R.
Berman,
J.
Zhong,
M.
Krogsgaard,
I.
Osman,
F.
Darvishian
(2016)
Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Human pathology, 57
-
O.
Abdel-Rahman,
M.
Fouad
(2016)
A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors.
Immunotherapy, 8 5
-
C.
Robert,
G.
Long,
B.
Brady,
C.
Dutriaux,
M.
Maio,
L.
Mortier,
J.
Hassel,
P.
Rutkowski,
C.
McNeil,
E.
Kalinka‐Warzocha,
K.
Savage,
M.
Hernberg,
C.
Lebbé,
J.
Charles,
C.
Mihalcioiu,
V.
Chiarion-Sileni,
C.
Mauch,
F.
Cognetti,
A.
Arance,
H.
Schmidt,
D.
Schadendorf,
H.
Gogas,
L.
Lundgren-Eriksson,
C.
Horak,
B.
Sharkey,
I.
Waxman,
V.
Atkinson,
P.
Ascierto
(2015)
Nivolumab in previously untreated melanoma without BRAF mutation.
The New England journal of medicine, 372 4
-
A.
Eggermont
(2010)
Advances in systemic treatment of melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 7
-
Z.
Cooper,
Dennie
Frederick,
Z.
Ahmed,
J.
Wargo
(2013)
Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
Oncoimmunology, 2
-
C.
Fortes,
S.
Mastroeni,
Thomas
Manooranparanpampil,
F.
Passarelli,
A.
Zappalà,
C.
Marino,
N.
Russo,
P.
Michelozzi
(2015)
Tumor-infiltrating lymphocytes predict cutaneous melanoma survival
Journal of Translational Medicine, 13
-
A.
Ladányi
(2015)
Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma
Pigment Cell & Melanoma Research, 28
-
R.
Siegel,
K.
Miller,
A.
Jemal
(2018)
Cancer statistics, 2018
CA: A Cancer Journal for Clinicians, 68
-
Yinan
Dong,
Qian
Sun,
Xinwei
Zhang
(2016)
PD-1 and its ligands are important immune checkpoints in cancer
Oncotarget, 8
-
F.
Tas,
S.
Keskin,
A.
Karadeniz,
N.
Dagoglu,
F.
Sen,
L.
Kılıç,
I.
Yıldız
(2012)
Noncutaneous Melanoma Have Distinct Features from Each Other and Cutaneous Melanoma
Oncology, 81
-
M.
Teng,
S.
Ngiow,
A.
Ribas,
M.
Smyth
(2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1.
Cancer research, 75 11
-
A.
Schietinger,
P.
Greenberg
(2014)
Tolerance and exhaustion: defining mechanisms of T cell dysfunction.
Trends in immunology, 35 2
-
Michele
Maio
(2012)
Melanoma as a model tumour for immuno-oncology.
Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 8
-
(2017)
Programmed cell death 1 (PD-1) ligand (PDL1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis
-
P.
Cooper,
H.
Wanebo,
R.
Hagar
(1985)
Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance.
Archives of dermatology, 121 9
-
N.
Lee,
L.
Zakka,
M.
Mihm,
T.
Schatton
(2016)
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.
Pathology, 48 2
-
S.
Lorenzo,
D.
Fanale,
B.
Corradino,
V.
Caló,
G.
Rinaldi,
V.
Bazan,
A.
Giordano,
A.
Cordova,
A.
Russo
(2016)
Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
Cancer Biology & Therapy, 17
-
M.
Mihm,
J.
Mulé
(2015)
Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response
Cancer Immunology Research, 3
-
K.
Dobbin,
A.
Cesano,
J.
Alvarez,
R.
Hawtin,
S.
Janetzki,
I.
Kirsch,
G.
Masucci,
P.
Robbins,
S.
Selvan,
H.
Streicher,
Jenny
Zhang,
L.
Butterfield,
M.
Thurin
(2016)
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations
Journal for Immunotherapy of Cancer, 4
-
M.
Chapon,
C.
Randriamampita,
E.
Maubec,
C.
Badoual,
Stéphane
Fouquet,
Shu-Fang
Wang,
E.
Marinho,
D.
Farhi,
M.
Garcette,
S.
Jacobelli,
A.
Rouquette,
A.
Carlotti,
A.
Girod,
A.
Prévost-Blondel,
A.
Trautmann,
M.
Avril,
N.
Bercovici
(2011)
Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.
The Journal of investigative dermatology, 131 6
-
N.
Thomas,
K.
Busam,
L.
From,
A.
Kricker,
B.
Armstrong,
H.
Anton-Culver,
S.
Gruber,
R.
Gallagher,
R.
Zanetti,
S.
Rosso,
T.
Dwyer,
A.
Venn,
P.
Kanetsky,
P.
Groben,
Honglin
Hao,
I.
Orlow,
A.
Reiner,
L.
Luo,
S.
Paine,
D.
Ollila,
H.
Wilcox,
C.
Begg,
M.
Berwick
(2013)
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 33
-
T.
Gajewski
(2006)
Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment
Clinical Cancer Research, 12
-
S.
Moschos,
Ramya
Pinnamaneni
(2015)
Targeted therapies in melanoma.
Surgical oncology clinics of North America, 24 2
-
C.
Kyi,
M.
Postow
(2014)
Checkpoint blocking antibodies in cancer immunotherapy
FEBS Letters, 588
-
Prognostic stratification of ulcerated melanoma
-
(2015)
Targeted therapies for solid tumors – A handbook for moving toward new frontiers in cancer treatment
-
Sylvain
Simon,
N.
Labarrière
(2017)
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Oncoimmunology, 7
-
Bingshan
Liu,
Yongping
Song,
Delong
Liu
(2017)
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Journal of Hematology & Oncology, 10
-
S.
Topalian
(2017)
Targeting Immune Checkpoints in Cancer Therapy.
JAMA, 318 17
-
M.
Bønnelykke-Behrndtz,
H.
Schmidt,
I.
Christensen,
T.
Damsgaard,
H.
Møller,
L.
Bastholt,
P.
Nørgaard,
T.
Steiniche
(2014)
Prognostic stratification of ulcerated melanoma: not only the extent matters.
American journal of clinical pathology, 142 6
-
R.
Davey,
A.
Westhuizen,
N.
Bowden
(2016)
Metastatic melanoma treatment: Combining old and new therapies.
Critical reviews in oncology/hematology, 98
-
V.
Lees,
J.
Briggs
(1993)
Cutaneous melanoma.
Journal of the American Academy of Dermatology, 29 2 Pt 1
-
J.
Larkin,
P.
Ascierto,
B.
Dréno,
V.
Atkinson,
G.
Liszkay,
M.
Maio,
M.
Mandalà,
L.
Demidov,
D.
Stroyakovskiy,
L.
Thomas,
L.
Cruz-Merino,
C.
Dutriaux,
C.
Garbe,
M.
Sovak,
I.
Chang,
N.
Choong,
S.
Hack,
G.
McArthur,
A.
Ribas
(2014)
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
The New England journal of medicine, 371 20
-
Z.
Xu-Monette,
Mingzhi
Zhang,
Jianyong
Li,
K.
Young
(2017)
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Frontiers in Immunology, 8
-
A.
Passarelli,
Francesco
Mannavola,
L.
Stucci,
M.
Tucci,
F.
Silvestris
(2017)
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Oncotarget, 8
-
Regression in thin malignant melanoma
-
BaSang
CiRen,
Xinhua
Wang,
Z.
Long
(2016)
The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis
Oncotarget, 7
-
Z-Y
Zheng,
W.
Bu,
Lin
Tian,
C.
Fan,
Xia
Gao,
Xinna
Zhang,
Cuijuan
Yu,
Hao
Wang,
Y.
Liao,
Yafang
Li,
M.
Lewis,
D.
Edwards,
T.
Zwaka,
S.
Hilsenbeck,
D.
Medina,
C.
Perou,
C.
Creighton,
X.
Zhang,
E.
Chang
(2016)
Abstract P2-06-11: Wild type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL8 secretion via JAK2 activation
Cancer Research, 75
-
S.
Ngiow,
D.
Knight,
A.
Ribas,
G.
McArthur,
M.
Smyth
(2013)
BRAF-targeted therapy and immune responses to melanoma
Oncoimmunology, 2
-
T.
Barnes,
E.
Amir
(2017)
HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
British Journal of Cancer, 117
-
T.
Hanna,
P.
Nguyen,
Tara
Baetz,
Christopher
Booth,
E.
Eisenhauer
(2018)
A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.
Clinical oncology (Royal College of Radiologists (Great Britain)), 30 10
-
J.
Obeid,
G.
Erdag,
M.
Smolkin,
D.
Deacon,
J.
Patterson,
Leiping
Chen,
T.
Bullock,
C.
Slingluff
(2016)
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome
OncoImmunology, 5
-
C.
Camisaschi,
V.
Vallacchi,
C.
Castelli,
L.
Rivoltini,
M.
Rodolfo
(2014)
Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment
Expert Review of Molecular Diagnostics, 14
-
G.
Badalamenti,
D.
Fanale,
L.
Incorvaia,
N.
Barraco,
A.
Listì,
R.
Maragliano,
B.
Vincenzi,
V.
Caló,
J.
Iovanna,
V.
Bazan,
A.
Russo
(2018)
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Cellular immunology
-
S.
Oba-Shinjo,
Mariangela
Correa,
T.
Ricca,
Fernanda
Molognoni,
M.
Pinhal,
I.
Neves,
Sueli
Marie,
L.
Sampaio,
H.
Nader,
R.
Chammas,
M.
Jasiulionis
(2006)
Melanocyte transformation associated with substrate adhesion impediment.
Neoplasia, 8 3
-
S.
Ferretti,
E.
Crocetti,
C.
Buzzoni
(2011)
[Italian cancer figures: North and South are getting closer].
Epidemiologia e prevenzione, 35 5-6 Suppl 2
-
P.
Ascierto,
K.
Flaherty,
Stephanie
Goff
(2018)
Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 38
-
G.
Long,
G.
Long,
V.
Atkinson,
V.
Atkinson,
J.
Cebon,
M.
Jameson,
B.
Fitzharris,
C.
McNeil,
A.
Hill,
A.
Ribas,
M.
Atkins,
John
Thompson,
W.
Hwu,
F.
Hodi,
A.
Menzies,
A.
Menzies,
A.
Guminski,
A.
Guminski,
R.
Kefford,
Benjamin
Kong,
Benjamin
Kong,
B.
Tamjid,
A.
Srivastava,
A.
Lomax,
Mohammed
Islam,
X.
Shu,
S.
Ebbinghaus,
N.
Ibrahim,
M.
Carlino,
M.
Carlino
(2017)
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
The Lancet. Oncology, 18 9